<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PAREMYD- hydroxyamphetamine hydrobromide and tropicamide solution </strong><br>Akorn, Inc.<br></p></div>
<h1>PAREMYD<span class="Sup">®</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s0"></a><a name="section-1"></a><p></p>
<p class="First">1%/0.25%<br><span class="Bold">Sterile</span></p>
<p><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s1"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">PAREMYD<span class="Sup">®</span> sterile ophthalmic solution is a topical mydriatic combination product for ophthalmic use.</p>
<p><span class="Bold">STRUCTURAL FORMULAE</span></p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da8a8a19-ac1b-4160-aac4-c4c57598eb5d&amp;name=par02-0000-01.jpg"></div>
<p><span class="Bold">CHEMICAL NAME</span><br>Hydroxyamphetamine hydrobromide: Phenol, 4-(2-aminopropyl)-, hydrobromide<br>Tropicamide: Benzeneacetamide, N-ethyl-α-(hydroxymethyl)-N-(4-pyridinylmethyl)-</p>
<p><span class="Bold">CONTAINS</span><br><span class="Bold">Actives:</span> Hydroxyamphetamine hydrobromide, USP.......................1.0%<br>        Tropicamide, USP.................................................................0.25%<br><span class="Bold">Preservative:</span> Benzalkonium Chloride 0.005%<br><span class="Bold">Inactives:</span> Edetate Disodium 0.015%, Sodium Chloride; Hydrochloric Acid and/or Sodium Hydroxide may be added to adjust pH (4.2 to 5.8 during its shelf life), and Purified Water. The <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of PAREMYD<span class="Sup">®</span> is approximately 307 mOsm/l.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s2"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">PAREMYD<span class="Sup">®</span> Solution combines the effects of the adrenergic agent, hydroxyamphetamine hydrobromide, and the anticholinergic agent, tropicamide.</p>
<p>Hydroxyamphetamine hydrobromide is an indirectly-acting sympathomimetic agent which, when applied topically to the eye, causes the release of endogenous norepinephrine from intact adrenergic nerve terminals resulting in <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>. Since hydroxyamphetamine hydrobromide has little or no direct activity on the receptor site, dilation does not usually occur if there is damage to the presynaptic nerve terminal, e.g., Horner's Syndrome. However, it is not known whether damage to the presynaptic nerve terminal will influence the extent of <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span> produced by PAREMYD<span class="Sup">®</span>. Hydroxyamphetamine hydrobromide has  minimal cycloplegic action.</p>
<p>Tropicamide is a parasympatholytic agent which, when applied topically to the eye, blocks the responses of the sphincter muscle of the iris and the ciliary muscle to cholinergic stimulation, producing dilation of the pupil and <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> of the ciliary muscle. Tropicamide produces short-duration <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>. Although <span class="product-label-link" type="condition" conceptid="375263" conceptname="Cycloplegia">cycloplegia</span> occurs with higher doses of tropicamide, there is evidence with 0.25% tropicamide that full <span class="product-label-link" type="condition" conceptid="375263" conceptname="Cycloplegia">cycloplegia</span> does not occur.</p>
<p>Since both these agents act on different effector sites, their simultaneous use produces an additive mydriatic effect. PAREMYD<span class="Sup">®</span> provides diminished pupil responsiveness to light, facilitating ophthalmoscopy. The onset of action with PAREMYD<span class="Sup">®</span> occurs within 15 minutes, followed by maximum effect within 60 minutes after instillation of one drop. Clinically significant dilation, inhibition of pupillary light response, and partial <span class="product-label-link" type="condition" conceptid="375263" conceptname="Cycloplegia">cycloplegia</span> last 3 hours, with recovery beginning at approximately 90 minutes and with complete recovery occurring in most patients in 6 to 8 hours. However, in some cases complete recovery may take up to 24 hours. Effectiveness may differ slightly in patients with light and dark irides, with those patients with light irides experiencing a slightly greater <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s3"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS</h1>
<p class="First">PAREMYD<span class="Sup">®</span> Solution is indicated for <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span> in routine diagnostic procedures and in conditions where short-term pupil dilation is desired. PAREMYD<span class="Sup">®</span> provides clinically significant <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span> with partial <span class="product-label-link" type="condition" conceptid="375263" conceptname="Cycloplegia">cycloplegia</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s4"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">PAREMYD<span class="Sup">®</span> Solution should not be used in patients with angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or in those with narrow angles in whom dilation of the pupil may precipitate an attack of angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. This product is also contraindicated in patients who are hypersensitive to any of its components.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s5"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">For topical ophthalmic use only; not for injection.</p>
<p>There is evidence that mydriatics may produce a transient elevation of intraocular pressure in patients with open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
<p>This preparation rarely may cause CNS disturbances which may be particularly dangerous in infants, children or the aged. <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic reactions</span>, behavioral disturbances and vasomotor or cardio-respiratory collapse have been reported with the use of anticholinergic drugs.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s6"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s7"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or cardiac disease (i.e., <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> or chronic <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>) should be monitored after instillation. The elderly and others in whom <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span> may be encountered following administration of PAREMYD<span class="Sup">®</span> Solution should also be monitored closely. To avoid inducing angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, an estimation of the depth of the angle of the anterior chamber should be made.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s8"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be advised not to touch the dropper tip to any surface since this may contaminate the solution. Patients should be advised to use caution when driving or engaging in other hazardous activities while pupils are dilated. Patients may experience <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span> and/or <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> and should protect their eyes in bright illumination when pupils are dilated. Parents should be warned not to get this preparation in their child's mouth and to wash their own hands and the child's hands following administration.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s9"></a><a name="section-7.3"></a><p></p>
<h2>Carcinogenesis, mutagenesis, impairment of fertility</h2>
<p class="First">No studies have been performed to evaluate the carcinogenic, mutagenic or impairment of fertility potential of PAREMYD<span class="Sup">®</span>.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s10"></a><a name="section-7.4"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="s11"></a><a name="section-7.4.1"></a><p></p>
<h3>Pregnancy Category C</h3>
<p class="First">Animal reproduction studies have not been conducted with PAREMYD<span class="Sup">®</span>. It is also not known whether PAREMYD<span class="Sup">®</span> can cause fetal harm when administered to a pregnant woman or can affect reproduction capability. PAREMYD<span class="Sup">®</span> should be given to a pregnant woman only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s12"></a><a name="section-7.5"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when PAREMYD<span class="Sup">®</span> is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s13"></a><a name="section-7.6"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established. PAREMYD<span class="Sup">®</span> may rarely cause CNS disturbances which may be dangerous in infants and children. <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic reactions</span>, behavioral disturbances and vasomotor or cardio-respiratory collapse in children have been reported with the use of anticholinergic drugs. (See <span class="Bold"><a href="#s5">WARNINGS</a></span>). Keep this and all medications out of the reach of children.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s14"></a><a name="section-7.7"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">No overall differences in safety or effectiveness have been observed between elderly and younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s15"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">Increased intraocular pressure</span> has been reported following use of mydriatics. Transient <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>, dryness of the mouth, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span> with or without <span class="product-label-link" type="condition" conceptid="4080997" conceptname="Corneal epithelial staining pattern">corneal staining</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span> and <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span> have been reported with the use of tropicamide and/or hydroxyamphetamine hydrobromide, and thus may occur with PAREMYD<span class="Sup">®</span> Solution. Central nervous system disturbances have also been reported. <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic reactions</span>, behavioral disturbances, and vasomotor or cardiorespiratory collapse have been reported with the use of anticholinergic drugs.</p>
<p>Rare but serious cardiovascular events, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span> and significant <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotensive episodes</span> have occurred shortly following PAREMYD<span class="Sup">®</span> instillation.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s16"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Ocular overdosage will cause dilation of the pupils. Systemic overdosage or ingestion of large doses may result in <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, sub-sternal <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="4318531" conceptname="Gastrointestinal irritation">gastrointestinal irritation</span>. Patients with systemic overdosage should be carefully monitored and treated symptomatically.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s17"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">One to two drops in the conjunctival sac. The onset of action with PAREMYD<span class="Sup">®</span> Solution occurs within 15 minutes followed by maximum effect within 60 minutes. Clinically significant dilation, inhibition of pupillary light response, and partial <span class="product-label-link" type="condition" conceptid="375263" conceptname="Cycloplegia">cycloplegia</span> last 3 hours.</p>
<p><span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">Mydriasis</span> will reverse spontaneously with time, typically in 6 to 8 hours. However, in some cases, complete recovery may take up to 24 hours.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s18"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">PAREMYD<span class="Sup">®</span> (hydroxyamphetamine hydrobromide/tropicamide ophthalmic solution) 1%/0.25% as a 15 mL solution in a 15 mL opaque white, low density polyethylene bottle with a natural low density polyethylene dropper tip and a red polypropylene cap.</p>
<p>15 mL - NDC 17478-704-12</p>
<div class="Section" data-sectionCode="44425-7">
<a name="s19"></a><a name="section-11.1"></a><p></p>
<h2>STORAGE</h2>
<p class="First">Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Note: Protect from light.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-12"></a><p></p>
<p class="First">Manufactured by:<br><span class="Bold">Akorn, Inc.</span><br>Lake Forest, IL 60045</p>
<p>PM00N<br>Rev. 07/2012</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s21"></a><a name="section-13"></a><p></p>
<p class="First">Container Label Principal Display Panel
</p>
<p>NDC 17478-704-12
</p>
<p>PAREMYD<span class="Sup">®</span></p>
<p>(hydroxyamphetamine
</p>
<p>hydrobromide/tropicamide
</p>
<p>ophthalmic solution) 1%/0.25%
</p>
<p>15 mL   Sterile    Rx only
</p>
<div class="Figure">
<a name="f02"></a><img alt="Container Label Principal Display Panel
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da8a8a19-ac1b-4160-aac4-c4c57598eb5d&amp;name=par02-0000-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s22"></a><a name="section-14"></a><p></p>
<p class="First">Carton Principal Display Panel
</p>
<p>NDC 17478-704-12
</p>
<p>[Akorn logo]
</p>
<p>PAREMYD<span class="Sup">®</span></p>
<p>(hydroxyamphetamine
</p>
<p>hydrobromide/tropicamide
</p>
<p>ophthalmic solution)
</p>
<p>1%/0.25%
</p>
<p>15 mL
</p>
<p>Sterile     Rx only
</p>
<div class="Figure">
<a name="f03"></a><img alt="Carton Principal Display Panel
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=da8a8a19-ac1b-4160-aac4-c4c57598eb5d&amp;name=par02-0000-03.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PAREMYD 		
					</strong><br><span class="contentTableReg">hydroxyamphetamine hydrobromide, tropicamide solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:17478-704</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Hydroxyamphetamine hydrobromide</strong> (Hydroxyamphetamine) </td>
<td class="formItem">Hydroxyamphetamine hydrobromide</td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Tropicamide</strong> (Tropicamide) </td>
<td class="formItem">Tropicamide</td>
<td class="formItem">2.5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Edetate Disodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium Chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Hydrochloric Acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium Hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Benzalkonium Chloride</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:17478-704-12</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">15 mL in 1 BOTTLE, DROPPER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019261</td>
<td class="formItem">01/30/1992</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Akorn, Inc.
							(062649876)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Akorn, Inc</td>
<td class="formItem"></td>
<td class="formItem">603980319</td>
<td class="formItem">MANUFACTURE(17478-704), ANALYSIS(17478-704), STERILIZE(17478-704), PACK(17478-704), LABEL(17478-704)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>af120012-4fed-4126-b227-fb50fba7bffa</div>
<div>Set id: da8a8a19-ac1b-4160-aac4-c4c57598eb5d</div>
<div>Version: 2</div>
<div>Effective Time: 20120830</div>
</div>
</div> <div class="DistributorName">Akorn, Inc.</div></p>
</body></html>
